WO2004014361A1 - Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity - Google Patents

Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity Download PDF

Info

Publication number
WO2004014361A1
WO2004014361A1 PCT/EP2003/008153 EP0308153W WO2004014361A1 WO 2004014361 A1 WO2004014361 A1 WO 2004014361A1 EP 0308153 W EP0308153 W EP 0308153W WO 2004014361 A1 WO2004014361 A1 WO 2004014361A1
Authority
WO
WIPO (PCT)
Prior art keywords
carob
content
process according
denatured
carob flour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/008153
Other languages
French (fr)
Other versions
WO2004014361A9 (en
Inventor
David Thomas Davies
John Stephen Elder
Andrew Keith Forrest
Richard Lewis Jarvest
Neil David Pearson
Robert John Sheppard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to JP2004526773A priority Critical patent/JP4515260B2/en
Priority to US10/522,058 priority patent/US20060040925A1/en
Priority to DE60307860T priority patent/DE60307860T2/en
Priority to EP03784064A priority patent/EP1539133B1/en
Priority to AU2003251474A priority patent/AU2003251474A1/en
Publication of WO2004014361A1 publication Critical patent/WO2004014361A1/en
Publication of WO2004014361A9 publication Critical patent/WO2004014361A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • Denatured carob flour and the process to obtain it described in this specification will be applied in industry to develop dietary fiber products rich in condensed tannins for human consumption.
  • Carob pulp is also rich in cyclitol and pinitol, a product that is transformed into inositol in the organism, a molecule of great interest for cell metabolism control (Bates SH, Jones RB, Bailey CJ. Insulin-like effect of pinitol. Br J Pharacol (2000) 130 (8): 1944-48).
  • the object of the present invention is, therefore, to eliminate from the carob pulp a large proportion of its sugars and soluble tannins, but maintaining a significant pinitol contents and to modify its condensed tannins to maintain its beneficial effects (hypolipaemic activity), regulators of intestinal function, antioxidants etc), eliminate its astringent and antinutritional effects and to be able to use in this way the product as a dietary product for human or animal use, as well as a component in pharmaceuticals.
  • the denatured carob flour with low soluble tannin and sugar contents has the following composition, depending on the variety of fruit used:
  • Cyclitols usually 0.2-1.5%; typically 0.3-1%
  • Lignins usually 2-10% ; typically 2-7%
  • Celluloses usually 10-30% ; typically 15-28%
  • Hemicelluloses usually 3-20% ; typically 3-9% Pectins usually 1-6%; typically 2-5%
  • Condensed tannins usually 25-55%; typically 30-48%
  • Protein usually 3-9%; typically 4-8% Water contents less than usually below 8%; typically below
  • This carob flour is characterized by having an active ingredient with at least 25%, usually 30%, typically 40% of condensed carob tannins denatured thermally with a weight ratio of soluble to insoluble polyphenols less than 0.05 (solubility determined with water at 37°C). Evaluation of the polyphenol contents has been carried out by first determining the soluble tannin contents in water at 37°C stirring for 15 minutes; these are determined spec trophotrometric ally in this water with the Folin-Ciocalteau reagent (Singleton N.L. Rossi J.A. Colorimetry of total phenolics with phosphomolybdicphosphotungstic acid reagents. Am. J. Enol. Nitic (1965). 16:144- 158).
  • the insoluble polyphenols of the residue are determined by treatment with HC1- butanol according to the method of Hagerman and coworkers (Hagerman A.E. Zhao Y. Jonson S. Methods for determination of condensed and hydrolyzable tannins. In F. Shahidi (Ed), Antinutrients and phytochemicals in foods (p. 209-222). ACS symposium Series 662. Washington, DC. American Chemical Society).
  • carob pulp rich in condensed tannins, formed by polymerization of flavan-3-ol and its gallic esters with a strong astringent effect, are treated with heat (between usually 130 and 200°C, typically 140 and 150°C) to result in a change of structure of the polyphenols with partial degradation and polymerization and to eliminate astringency and interference with absorption of nutrients in the diet but maintaining most of its positive effects.
  • the process to obtain the previously described carob flour consists in a series of steps, as follows: a. Cleaning the whole fruit: Cleaning includes e.g dry (e.g. mechanical separation of contaminants) or wet (e.g. wash out with water) cleaning steps. Dependent on the cleaning procedure this step may additionally include a drying step. This could be done e.g. in an air flow, b. Crushing the carob fruits: this could be done, e.g. by passing the carob fruit through a mill, typically a hammer mill, to shred the pods to pieces smaller than 3 cm. c.
  • a. Cleaning the whole fruit Cleaning includes e.g dry (e.g. mechanical separation of contaminants) or wet (e.g. wash out with water) cleaning steps. Dependent on the cleaning procedure this step may additionally include a drying step. This could be done e.g. in an air flow, b. Crushing the carob fruits: this could be done, e.g. by passing the carob fruit through a mill, typically a
  • the seed can be separated using a sieve with a suitably sized mesh, depending on the conditions of the process, the agronomical variety and the water contents of the fruit.
  • air classification or other mechanical or physical technologies can be used.
  • Toasting modification of the structure of condensed tannins: this process is important to change the nutritional properties of the condensed tannins. This can be reached by toasting of the carob kibbles at temperatures usually between 130-200°C, typically between 140-150°C for a certain time period depending on the water content of the pulp and the particle size. Usual time periods for this toasting process are 5-60 minutes, typically 10-20 minutes.
  • Extraction process the toasted carob pulp is extracted with water or any other suitable solvent to remove the sugars and water-soluble tannins.
  • the ratio of extraction material to solvent is usually higher than 1:20 (by weight), typically 1:4 (by weight).
  • the extraction can be made at different temperatures usually in the range of 5-80°C, typically between 20-55°C.
  • Extraction can be done e.g. in an simple extraction tank (with or without stirrer) or in a continuously operating extractor (counter current flow extraction). Dependent on the other extraction parameters extraction time usually lies between 5 minutes to 24 hours, typically between 15 minutes and 2 hours.
  • Separation Separation of the water soluble components from the water insoluble parts can be done by several techniques including decantation, filtration, or centrifugation.
  • Milling the water-insoluble residue is ground to a fine powder by milling techniques. Preferred equipment is a colloidal mill, but also other milling techniques can be considered (e.g. ball mills). Reached particle sizes are below
  • 250 ⁇ m (90% of particles below 250 ⁇ m), usually below 150 ⁇ m (90% of particles below 150 ⁇ m) and typically below 100 ⁇ m (90% of particles below
  • steps e. (extraction) and f. (separation) are sufficient to reach sugar contents usually below 15 % and typically below 10% in the insoluble residue.
  • steps e. (extraction) and f. (separation) are sufficient to reach sugar contents usually below 15 % and typically below 10% in the insoluble residue.
  • i. Separation After the last extraction step the obtained residue is pressed, filtered, decanted, or centrifuged to eliminate as much as possible of the water, j. Drying: To reduce the water content usually below 8%, typically below 6%.
  • the whole production process, as described above in the steps a-k, or parts of it, can also be done in a continuous way.
  • DCF Dynamic Carob Fibre
  • the DCF increases fecal volume and weight compared to cellulose and results in a similar fecal volume and weight, at the same doses, as NCF, but with fecal butyrate and polyphenol concentrations 30% and 10% higher, respectively, in rats fed with our invention than in those fed with diets containing carob fiber (NCF), hence, as repeatedly described by several authors, protection against the formation of mutagenic or carcinogenic compounds (electrophylic molecules) in animals that consume DCF is higher than that achieved with carob fibers (NCF).
  • NCF carob fiber

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man.

Description

DENATURED CAROB FLOUR (DCF) WITH A LOW CONTENT OF SOLUBLE TANNINS AND SUGARS, MEANT FOR HUMAN CONSUMPTION
AND PROCESS TO OBTAIN IT.
FIELD OF THE INVENTION
Denatured carob flour and the process to obtain it described in this specification will be applied in industry to develop dietary fiber products rich in condensed tannins for human consumption.
DESCRIPTION OF PRIOR ART
There is considerable interest in developing dietary fiber products rich in polyphenol compounds owing to the known protective role of these substances against cardiovascular disease by reducing hypercholesterolemia and their effects on the efficacy of the intestinal translocation and the prevention of colonic cancer.
Hence, to cite some studies from the literature, polyphenolic compounds present in different concentrations in dietary fiber and in different food compounds have important antioxidant effects (Pulido R, Bravo L, Saura-Calixto F. Antioxidant activity of dietary polyphenols as determined by a modified ferric reducing/antioxidant power assay. J Agric Food Chem (2000) 48(8): 3396-402), that can be used to prevent and treat certain diseases including cancer (Pool-Zobel BL, Adlercreutz H, Glei M, Liegibel UM, Sittlingon J., Rowland I., Wahala K, Rechkemmer G. Isoflavonoids and lignans have different potentials to modulate oxidative genetic damage in human colon cells). Carcinogenesis (2000) 21(6): 1247-52). Nevertheless, there is only a small amount, of condensed tannins in the different dietary fibers and products enriched in these natural polyphenols cannot be used in the chronic treatment of degenerative diseases because at these levels they have a strong astringent and antinutritional effect.
On the other hand, pectins, gums and other similar products, majority components of soluble fibers, although substances produced by their colonic fermentation (e.g. butyrate) have been found to have potentially therapeutic applications, important benefits for the immune system (Perez R. Stevenson f. Jhonson J., Morgan M., Ericson K. Hubbard N.E. Morand L. Ruduch S., Kaztnelson S. Sodium butyrate upregulates Kupffer cells PGE-2 production and modulates immune function. J. Surg. Res. (1998) 78, 1-6; Lim B.O. Yamada K. Nonaka M. Kuramoto Y., Hung P., Sugano M. Dietary fibres modulate indices of intestinal immune function in rats. J. Nutr. (1997) 127, 663-7.) and in the prevention of colonic cancer in cell culture studies (Sowa Y, Sakai T. Butyrate as a model for "gene-regulating chemoprevention and chemotherapy''' biofactors (2000); 12 (1-4): 283-7), in human trials the results are not as clear, probably because they ferment rapidly in the proximal colon and little butyrate arrives at the distal colon, the most common site of neoplasic processes (Perrin P, Pierre F, Patry Y, Champ M, Berreur M, Pardal G, Bornet F, Meflah K, Menanteau J. Only fibers promoting a stable butyrate producing colonic ecosystem decrease the rate of aberrant crypt foci in rats. Gut. (2001) 48(1): 53-61). Nevertheless, mainly because of economic interest in animal production, the delaying effect of tannins on bacterial fermentation in the digestive tract is currently well known. Therefore, in suitable quantities they can regulate and delay the production of butyrate in the final portions of the colon and rectum.
Carob pulp is also rich in cyclitol and pinitol, a product that is transformed into inositol in the organism, a molecule of great interest for cell metabolism control (Bates SH, Jones RB, Bailey CJ. Insulin-like effect of pinitol. Br J Pharacol (2000) 130 (8): 1944-48). The object of the present invention is, therefore, to eliminate from the carob pulp a large proportion of its sugars and soluble tannins, but maintaining a significant pinitol contents and to modify its condensed tannins to maintain its beneficial effects (hypolipaemic activity), regulators of intestinal function, antioxidants etc), eliminate its astringent and antinutritional effects and to be able to use in this way the product as a dietary product for human or animal use, as well as a component in pharmaceuticals.
DESCRIPTION OF THE INVENTION
The denatured carob flour with low soluble tannin and sugar contents, described here, has the following composition, depending on the variety of fruit used:
Sugars usually 2-15%, typically 3-10%
Cyclitols (pinitol) usually 0.2-1.5%; typically 0.3-1%
Lignins usually 2-10% ; typically 2-7%
Celluloses usually 10-30% ; typically 15-28%
Hemicelluloses usually 3-20% ; typically 3-9% Pectins usually 1-6%; typically 2-5%
Condensed tannins usually 25-55%; typically 30-48%
Protein usually 3-9%; typically 4-8% Water contents less than usually below 8%; typically below
All percentages given are weight percentages (wt.-%) if not stated otherwise.
This carob flour is characterized by having an active ingredient with at least 25%, usually 30%, typically 40% of condensed carob tannins denatured thermally with a weight ratio of soluble to insoluble polyphenols less than 0.05 (solubility determined with water at 37°C). Evaluation of the polyphenol contents has been carried out by first determining the soluble tannin contents in water at 37°C stirring for 15 minutes; these are determined spec trophotrometric ally in this water with the Folin-Ciocalteau reagent (Singleton N.L. Rossi J.A. Colorimetry of total phenolics with phosphomolybdicphosphotungstic acid reagents. Am. J. Enol. Nitic (1965). 16:144- 158). The insoluble polyphenols of the residue are determined by treatment with HC1- butanol according to the method of Hagerman and coworkers (Hagerman A.E. Zhao Y. Jonson S. Methods for determination of condensed and hydrolyzable tannins. In F. Shahidi (Ed), Antinutrients and phytochemicals in foods (p. 209-222). ACS symposium Series 662. Washington, DC. American Chemical Society).
In this invention, carob pulp, rich in condensed tannins, formed by polymerization of flavan-3-ol and its gallic esters with a strong astringent effect, are treated with heat (between usually 130 and 200°C, typically 140 and 150°C) to result in a change of structure of the polyphenols with partial degradation and polymerization and to eliminate astringency and interference with absorption of nutrients in the diet but maintaining most of its positive effects. It can, therefore, be used for human diet and nutrition (as ordinary foods, enriched foods, dietary foods, foods for special medical purposes or dietary supplements), without antinutritional problems, while the effects of these condensed tannins as a sequesterant of cholesterol and bile salts, as antioxidants, laxatives and regulators of intestinal fermentation are maintained. Furthermore applications in animal feed and pet food or in human and animal pharmaceuticals are possible.
The process to obtain the previously described carob flour consists in a series of steps, as follows: a. Cleaning the whole fruit: Cleaning includes e.g dry (e.g. mechanical separation of contaminants) or wet (e.g. wash out with water) cleaning steps. Dependent on the cleaning procedure this step may additionally include a drying step. This could be done e.g. in an air flow, b. Crushing the carob fruits: this could be done, e.g. by passing the carob fruit through a mill, typically a hammer mill, to shred the pods to pieces smaller than 3 cm. c. Separation of carob seeds and kibbled carob pulp: the seed can be separated using a sieve with a suitably sized mesh, depending on the conditions of the process, the agronomical variety and the water contents of the fruit. As an alternative suitable process air classification or other mechanical or physical technologies can be used. d. Toasting (modification of the structure of condensed tannins): this process is important to change the nutritional properties of the condensed tannins. This can be reached by toasting of the carob kibbles at temperatures usually between 130-200°C, typically between 140-150°C for a certain time period depending on the water content of the pulp and the particle size. Usual time periods for this toasting process are 5-60 minutes, typically 10-20 minutes. e. Extraction process: the toasted carob pulp is extracted with water or any other suitable solvent to remove the sugars and water-soluble tannins. The ratio of extraction material to solvent is usually higher than 1:20 (by weight), typically 1:4 (by weight). The extraction can be made at different temperatures usually in the range of 5-80°C, typically between 20-55°C. Extraction can be done e.g. in an simple extraction tank (with or without stirrer) or in a continuously operating extractor (counter current flow extraction). Dependent on the other extraction parameters extraction time usually lies between 5 minutes to 24 hours, typically between 15 minutes and 2 hours. f. Separation: Separation of the water soluble components from the water insoluble parts can be done by several techniques including decantation, filtration, or centrifugation. g. Milling: the water-insoluble residue is ground to a fine powder by milling techniques. Preferred equipment is a colloidal mill, but also other milling techniques can be considered (e.g. ball mills). Reached particle sizes are below
250 μm (90% of particles below 250 μm), usually below 150 μm (90% of particles below 150 μm) and typically below 100 μm (90% of particles below
100 μm). h. Optionally repetition of steps e. (extraction) and f. (separation) to further reduce the water soluble constituents in the obtained residue. Two further extraction steps are sufficient to reach sugar contents usually below 15 % and typically below 10% in the insoluble residue. i. Separation: After the last extraction step the obtained residue is pressed, filtered, decanted, or centrifuged to eliminate as much as possible of the water, j. Drying: To reduce the water content usually below 8%, typically below 6%.
This can be managed by several drying techniques including a drying oven, spray drying, vacuum drying, drying in an air or inert gas stream. Temperatures should usually not lie above 140°C, typically not above 60-65°C. k. Classification (sieving): dependent on the application the obtained product can be sieved to obtain standardized particle size limits.
The whole production process, as described above in the steps a-k, or parts of it, can also be done in a continuous way.
The properties of this denatured carob flour: hypocholesterolemiant, regulator of gastrointestinal dynamics, bile salt chelant and antioxidant on which we base its potential dietary and pharmacological applications for both human and animals, have been demonstrated in a number of animal trials carried out in the Department of Nutrition of the Universidad Complutense de Madrid, of which we summarize some relevant results.
First of all, in experimental animals the influence of this denatured carob flour
(DCF) on ingestion, weight increase, growth, fecal volume, fecal polyphenol and butyrates was studied. To do this, a total of three batches of 10 growing rats were fed isocaloric synthetic diets modified to suit their nutritional requirements in which the only variable was the type of dietary fiber used: 2% apple pectin in all batches as butyrate source and 5% in batch 1 of microcrystalline cellulose (Avicel R), 5% in batch 2 of carob fiber (NCF = Natural Carob Fibre) and 5% in batch 3 of DCF. It was found that intake of DCF did not affect weight increase in animals or the dietary efficacy of the diets compared to cellulose and it can, therefore, be concluded that the treatment has managed to eliminate the antinutritive effect of its condensed tannins, while the carob fiber (NCF), slightly but significantly reduces both parameters. The DCF increases fecal volume and weight compared to cellulose and results in a similar fecal volume and weight, at the same doses, as NCF, but with fecal butyrate and polyphenol concentrations 30% and 10% higher, respectively, in rats fed with our invention than in those fed with diets containing carob fiber (NCF), hence, as repeatedly described by several authors, protection against the formation of mutagenic or carcinogenic compounds (electrophylic molecules) in animals that consume DCF is higher than that achieved with carob fibers (NCF). To determine its effects on blood lipids, 30 young rats with experimental hypercholesterolemia were used (total cholesterol 235 mg/dl), 5 groups with 10 rats each were formed and the following fiber sources were added to their diets:
Batch 1-10% cellulose
Batch 2-10% carob fiber (NCF)
Batch 3-10 % carob flour (DCF)
After three weeks of treatment mean serum cholesterol levels were:
Batch 1: 285 mg/dl Batch 2: 165 mg/dl Batch 3-112 mg/dl
The conclusions of this study can be summarized as follows:
Taking into account that the cellulose used had no effect on cholesterolemia and that our invention (DCF) produced, significantly (p<0.05), the greatest reduction in serum cholesterol levels in animals, we can conclude that our invention has a more pronounced effect on cholesterolemia than natural carob fibers (NCF). This effect seems to be mediated by more sequestration of bile salts by DCF.
The percentages, temperatures and other additional factors associated with the product and with the process described can be variable provided that they are additional and secondary and do not alter the essence of the patent described here.

Claims

CLAIMS:
1. Denatured carob flour, characterized in that it comprises:
2-15%Sugars, 0.2-1.5%Cyclitols (pinitol), 2-10% Lignins, 10-30% Celluloses, 3- 20% Hemicelluloses, 1-6% Pectins, 25-55%Condensed tannins, 3-9% Protein and less than 8% Water.
2. Denatured carob flour according to claim 1, wherein the Sugar content is 3-10%.
3. Denatured carob flour according to claim 1 or 2, wherein the Cyclitols content is 0.3-1%.
4. Denatured carob flour according to one of claims 1-3, wherein the Lignins content is 2-7%.
5. Denatured carob flour according to one of claims 1-4, wherein the Celluloses content is 15-28%.
6. Denatured carob flour according to one of claims 1-5, wherein the Hemicelluloses content is 3-9%.
7. Denatured carob flour according to one of claims 1-6, wherein the Pectins content is 2-5%.
8. Denatured carob flour according to one of claims 1-7, wherein the Condensed Tannions content is 30-48%.
9. Denatured carob flour according to one of claims 1-8, wherein the Protein content is 4-8%.
10. Denatured carob flour according to one of claims 1-9, wherein the Water content is less than 6%.
11. Process to obtain a flour according to claim 1, comprising the following steps: a. Cleaning the whole fruit; b. Crushing the carob fruits; c. Separation of carob seeds and kibbled carob pulp; d. Toasting between 130-200°C e. Extraction process; f. Separation: g. Milling: 90% of particles below 250 μm h. Separation: i. Drying: below 8%, j. Classification (sieving):
12. Process according to claim 11, wherein in step b. the carob pod is shredded into pieces smaller than 3 cm.
13. Process according to claim 11 or 12, wherein the temperature is between 140-150°C
14. Process according to one of claims 11-13, wherein the time period for the toasting process is 5-60 minutes
15. Process according to claim 14, wherein the time period is 10-20 minutes.
16. Process according to one of claims 11-15, wherein in step e. the extraction is performed in the range of 5-80°C.
17. Process according to one of claims 11-16, wherein in step e. the ratio of pulp to water is 1:20 (wt./wt).
18. Process according to one of claims 11-17, wherein in step e. the extraction is performed for 5 minutes to 24 hours.
19. Process according to one of claims 11-18, wherein in step g. 90% of particles are below 150 μm.
20. Process according to one of claims 11-19, wherein between steps g. and h. steps e. and f. are at least once repeated.
21. Process according to one of claims 11-20, wherein in step i. the drying is performed at a temperature which does not exceed 140 °C.8%
22. Process according to one of claims 11-21, wherein the process is carried out continuously.
23. The use of the flour according to claim 1 in foods, dietary supplements, animal feed, pet food, human and animal medicine.
PCT/EP2003/008153 2002-07-25 2003-07-23 Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity Ceased WO2004014361A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2004526773A JP4515260B2 (en) 2002-07-25 2003-07-23 Aminocyclohexene quinoline and its azaisosteric analogs with antibacterial activity
US10/522,058 US20060040925A1 (en) 2002-07-25 2003-07-23 Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity
DE60307860T DE60307860T2 (en) 2002-07-25 2003-07-23 Aminocyclohexenchinolines and their azaisosteric analogues with antibacterial activity
EP03784064A EP1539133B1 (en) 2002-07-25 2003-07-23 Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity
AU2003251474A AU2003251474A1 (en) 2002-07-25 2003-07-23 Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0217294.8A GB0217294D0 (en) 2002-07-25 2002-07-25 Medicaments
GB0217294.8 2002-07-25

Publications (2)

Publication Number Publication Date
WO2004014361A1 true WO2004014361A1 (en) 2004-02-19
WO2004014361A9 WO2004014361A9 (en) 2004-04-08

Family

ID=9941121

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008153 Ceased WO2004014361A1 (en) 2002-07-25 2003-07-23 Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity

Country Status (9)

Country Link
US (1) US20060040925A1 (en)
EP (1) EP1539133B1 (en)
JP (1) JP4515260B2 (en)
AT (1) ATE336995T1 (en)
AU (1) AU2003251474A1 (en)
DE (1) DE60307860T2 (en)
ES (1) ES2270142T3 (en)
GB (1) GB0217294D0 (en)
WO (1) WO2004014361A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010040A3 (en) * 2004-07-09 2006-05-04 Glaxo Group Ltd Antibacterial agents
US7109213B2 (en) 2002-01-29 2006-09-19 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
US7232832B2 (en) 2002-11-05 2007-06-19 Smithkline Beecham Corporation Antibacterial agents
WO2007086016A1 (en) 2006-01-26 2007-08-02 Actelion Pharmaceuticals Ltd Tetrahydropyrane antibiotics
WO2007115947A1 (en) 2006-04-06 2007-10-18 Glaxo Group Limited Pyrrolo-quinoxalinone derivatives as antibacterials
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
WO2008003690A1 (en) 2006-07-03 2008-01-10 Glaxo Group Limited Azatricyclic compounds and their use
WO2008009700A1 (en) 2006-07-20 2008-01-24 Glaxo Group Limited Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
US7491714B2 (en) 2002-12-04 2009-02-17 Glaxo Group Limited Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
US7498326B2 (en) 2002-06-26 2009-03-03 Glaxo Group Limited Compounds
EP2080761A1 (en) 2008-01-18 2009-07-22 Glaxo Group Limited Compounds
US7618959B2 (en) 2002-11-05 2009-11-17 Smithklinebeecham Corp Antibacterial agents
US7622481B2 (en) 2002-06-26 2009-11-24 Glaxo Group Limited Antibacterial compounds
US7691850B2 (en) 2004-06-15 2010-04-06 Glaxo Group Limited Antibacterial agents
WO2010043714A1 (en) 2008-10-17 2010-04-22 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials
US7709496B2 (en) 2006-04-06 2010-05-04 Glaxo Group Limited Antibacterial agents
WO2010081874A1 (en) 2009-01-15 2010-07-22 Glaxo Group Limited Naphthyridin-2 (1 h)-one compounds useful as antibacterials
US7875715B2 (en) 2005-06-16 2011-01-25 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
US7999115B2 (en) 2006-08-30 2011-08-16 Actelion Pharmaceutical Ltd. Spiro antibiotic derivatives
US9127002B2 (en) 2012-02-10 2015-09-08 Actelion Pharmaceuticals Ltd Process for manufacturing a naphthyridine derivative
WO2016027249A1 (en) 2014-08-22 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection
WO2017029602A2 (en) 2015-08-16 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Compounds for use in antibacterial applications
EP3896066A2 (en) 2015-08-07 2021-10-20 Bayer CropScience Aktiengesellschaft 2-(het)aryl-substituted condensed heterocycle derivatives as pesticides

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0118238D0 (en) * 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
AR042486A1 (en) * 2002-12-18 2005-06-22 Glaxo Group Ltd QUINOLINE AND NAFTIRIDINE COMPOSITE HALOSUSTITUDED IN POSITION 3, PROCEDURE TO PREPARE THE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION.
JP2009527562A (en) * 2006-02-21 2009-07-30 アムゲン インコーポレイティッド Cinnoline derivatives as phosphodiesterase 10 inhibitors
AU2007221049A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
WO2007103554A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
NZ579877A (en) * 2007-04-20 2011-09-30 Glaxo Group Ltd Tricyclic nitrogen containing compounds as antibacterial agents
EP2890698B1 (en) * 2012-08-30 2017-03-01 F. Hoffmann-La Roche AG Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use
EP4045485A1 (en) 2019-10-18 2022-08-24 The Regents Of The University Of California 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders
US12590298B2 (en) 2019-10-18 2026-03-31 The Regents Of The University Of California Ex vivo tumor angiogenesis model
CN119161260A (en) * 2024-06-26 2024-12-20 安徽大学 A method for synthesizing 1-(2-amino-4-fluoro-5-methoxyphenyl)-1-acetone

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078748A1 (en) * 1999-06-21 2000-12-28 Smithkline Beecham P.L.C. Quinoline derivatives as antibacterials
WO2001007432A2 (en) * 1999-07-23 2001-02-01 Smithkline Beecham P.L.C. Aminopiperidine derivatives as antibacterials
WO2001007433A2 (en) * 1999-07-23 2001-02-01 Smithkline Beecham P.L.C. Quinoline derivatives and their use as antibacterial agents
WO2002008224A1 (en) * 2000-07-26 2002-01-31 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
WO2002056882A1 (en) * 2001-01-22 2002-07-25 Smithkline Beecham P.L.C. Quinolines and nitrogenated derivaive thereof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015106A1 (en) * 1994-11-10 1996-05-23 Pfizer Pharmaceuticals Inc. Aryloxycycloalkenyl and aryloxyiminocycloalkenylhydroxyureas as 5-lipoxygenase inhibitors
DE69908555T2 (en) * 1998-01-26 2004-05-06 Smithkline Beecham P.L.C., Brentford CHINOLINE DERIVATIVES AS AN ANTIBACTERIAL MEDICINAL PRODUCT
GB9822450D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
JP2002535323A (en) * 1999-01-20 2002-10-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Piperidinylquinoline as a protein kinase inhibitor
FR2816618B1 (en) * 2000-11-15 2002-12-27 Aventis Pharma Sa HETEROCYCLYLALCOYL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM
GB0031088D0 (en) * 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078748A1 (en) * 1999-06-21 2000-12-28 Smithkline Beecham P.L.C. Quinoline derivatives as antibacterials
WO2001007432A2 (en) * 1999-07-23 2001-02-01 Smithkline Beecham P.L.C. Aminopiperidine derivatives as antibacterials
WO2001007433A2 (en) * 1999-07-23 2001-02-01 Smithkline Beecham P.L.C. Quinoline derivatives and their use as antibacterial agents
WO2002008224A1 (en) * 2000-07-26 2002-01-31 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
WO2002056882A1 (en) * 2001-01-22 2002-07-25 Smithkline Beecham P.L.C. Quinolines and nitrogenated derivaive thereof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109213B2 (en) 2002-01-29 2006-09-19 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
US7622481B2 (en) 2002-06-26 2009-11-24 Glaxo Group Limited Antibacterial compounds
US7498326B2 (en) 2002-06-26 2009-03-03 Glaxo Group Limited Compounds
US7232832B2 (en) 2002-11-05 2007-06-19 Smithkline Beecham Corporation Antibacterial agents
US7618959B2 (en) 2002-11-05 2009-11-17 Smithklinebeecham Corp Antibacterial agents
US7491714B2 (en) 2002-12-04 2009-02-17 Glaxo Group Limited Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
US7691850B2 (en) 2004-06-15 2010-04-06 Glaxo Group Limited Antibacterial agents
WO2006010040A3 (en) * 2004-07-09 2006-05-04 Glaxo Group Ltd Antibacterial agents
US8124602B2 (en) 2005-06-16 2012-02-28 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
US7875715B2 (en) 2005-06-16 2011-01-25 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2007086016A1 (en) 2006-01-26 2007-08-02 Actelion Pharmaceuticals Ltd Tetrahydropyrane antibiotics
US7709496B2 (en) 2006-04-06 2010-05-04 Glaxo Group Limited Antibacterial agents
WO2007115947A1 (en) 2006-04-06 2007-10-18 Glaxo Group Limited Pyrrolo-quinoxalinone derivatives as antibacterials
WO2008003690A1 (en) 2006-07-03 2008-01-10 Glaxo Group Limited Azatricyclic compounds and their use
WO2008009700A1 (en) 2006-07-20 2008-01-24 Glaxo Group Limited Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
US7999115B2 (en) 2006-08-30 2011-08-16 Actelion Pharmaceutical Ltd. Spiro antibiotic derivatives
EP2080761A1 (en) 2008-01-18 2009-07-22 Glaxo Group Limited Compounds
WO2010043714A1 (en) 2008-10-17 2010-04-22 Glaxo Group Limited Tricyclic nitrogen compounds used as antibacterials
WO2010081874A1 (en) 2009-01-15 2010-07-22 Glaxo Group Limited Naphthyridin-2 (1 h)-one compounds useful as antibacterials
US9127002B2 (en) 2012-02-10 2015-09-08 Actelion Pharmaceuticals Ltd Process for manufacturing a naphthyridine derivative
WO2016027249A1 (en) 2014-08-22 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection
EP3639824A1 (en) 2014-08-22 2020-04-22 GlaxoSmithKline Intellectual Property Development Limited Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection
EP3896066A2 (en) 2015-08-07 2021-10-20 Bayer CropScience Aktiengesellschaft 2-(het)aryl-substituted condensed heterocycle derivatives as pesticides
EP3896065A1 (en) 2015-08-07 2021-10-20 Bayer CropScience Aktiengesellschaft 2-(het)aryl-substituted condensed heterocycle derivatives as pesticides
WO2017029602A2 (en) 2015-08-16 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Compounds for use in antibacterial applications

Also Published As

Publication number Publication date
AU2003251474A1 (en) 2004-02-25
AU2003251474A8 (en) 2004-02-25
DE60307860T2 (en) 2007-10-11
EP1539133B1 (en) 2006-08-23
US20060040925A1 (en) 2006-02-23
WO2004014361A9 (en) 2004-04-08
ATE336995T1 (en) 2006-09-15
GB0217294D0 (en) 2002-09-04
JP2005538125A (en) 2005-12-15
JP4515260B2 (en) 2010-07-28
EP1539133A1 (en) 2005-06-15
DE60307860D1 (en) 2006-10-05
ES2270142T3 (en) 2007-04-01

Similar Documents

Publication Publication Date Title
EP1539133A1 (en) Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity
US6855359B2 (en) Soluble isoflavone compositions
WO2009014758A1 (en) Process of making theaflavins enriched tea extract
EP1549156B1 (en) Denatured carob flour (dcf) with a low content of soluble tannins and sugars, meant for human consumption and process to obtain it
CA2517668A1 (en) Process for producing proanthocyanin-rich material
JP2003146898A (en) Hyperlipidemia improver
WO2012067491A2 (en) Compositions comprising extracts obtained from oil palm based materials for providing anti -inflammatory effects and method of producing thereof
KR101082938B1 (en) Vitamin composition of which water-soluble vitamin is enriched and preparation method thereof
JPH09262066A (en) Food product and medicinal composition for inhibiting hyperlipemia
US9132159B2 (en) Composition for prevention and/or treatment of tumors containing acacia derivative
JPH0840923A (en) Nutrient-supplying agent
JP6778506B2 (en) Functional food composition
KR20180130957A (en) Manufacture method of increasing functional content and food composition comprising extract from young barley leaves
US20060251744A1 (en) Method for preparing ginkgo extracts having a reduced content of polycyclic aromatic hydrocarbons
JP2009107952A (en) Anti-osteoporosis agent
ES2602877B1 (en) PROCEDURE FOR OBTAINING A CONCENTRATE OF POLYMER PROANTOCIANIDINS WITH A CONTENT OVER 90% THROUGH ENZYMATIC TREATMENTS AND WITHOUT USING ORGANIC SOLVENTS
JP2002371001A (en) Prophylactic or therapeutic agent for cataract
US8178135B2 (en) Aqueous solution of conophylline and/or conophyllidine
JP2008503542A (en) Plant-derived product containing proanthocyanidins and process for producing the same
JP2003321362A (en) Food composition and medicament composition
KR20250133531A (en) A composition that uses Indirubin, Decursinol, and bamboo to prevent hair loss
CN117442701A (en) A kind of tea and traditional Chinese medicine composition for improving immunity and preparation method thereof
WO2023224134A1 (en) Composition for improving cognitive ability using water soluble curcumin and boswellia extracts
KR20240035028A (en) Composition for Improving Cognitive Ability Using Water-Soluble Curcumin and Wheat Bran Extracts
CN113874003A (en) Method and composition for continuous extraction and purification of unique flavan-3-ol extracts from immature whole grape vines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: DUE TO A SCANNING ERROR DURING THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION, REPLACE ALL PAGES BY CORRECT PAGES (59 PAGES)

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003784064

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004526773

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003784064

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006040925

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10522058

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10522058

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2003784064

Country of ref document: EP